Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity
Open Access
- 15 December 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (24) , 11840-11850
- https://doi.org/10.1158/0008-5472.can-06-1200
Abstract
Among the best-characterized genetic alterations in gliomas is the amplification of the epidermal growth factor receptor (EGFR) gene, present in ∼40% of glioblastoma multiforme, and frequently associated with the EGFRvIII gene rearrangement. We have previously shown that attenuated vaccine strains of measles virus have potent antitumor activity against gliomas, and identified H protein mutations, which ablate recognition of the natural measles virus receptors CD46 and SLAM. Retargeted recombinant viruses were generated from the measles Edmonston-NSe vaccine strain displaying a single-chain antibody against EGFRvIII at the COOH terminus of H and containing the marker green fluorescent protein (GFP) gene in position 1. Two different H mutants were employed: HSNS (V451S, Y481N, and A527S)-CD46 blind, and HAA (Y481A and R533A)-CD46 and SLAM blind. MV-GFP virus was used as a positive control. Both EGFRvIII-retargeted viruses had significant antitumor activity against EGFRvIII-expressing glioblastoma multiforme but no cytopathic effect against normal cells. In an orthotopic model of EGFRvIII-expressing GBM39 xenografts, there was comparable therapeutic efficacy between retargeted strains and unmodified MV-GFP and statistically significant prolongation of survival in treated animals compared with the control group (P = 0.001). Formation of syncytia was observed in tumors treated with retargeted viruses, with a surrounding infiltrate consisting of macrophages and natural killer cells. In summary, EGFRvIII-retargeted oncolytic measles virus strains have comparable therapeutic efficacy with the unmodified MV-GFP strain against EGFRvIII-expressing glioma lines and xenografts with improved therapeutic index, a finding with potential translational implications in glioma virotherapy. (Cancer Res 2006; 66(24): 11840-50)Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- 957. Effect of Ligand Binding Affinity and Receptor Density in Relation to Biology of Retargeted VirusesMolecular Therapy, 2006
- Rescue and propagation of fully retargeted oncolytic measles virusesNature Biotechnology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles VirusCancer Research, 2004
- Antibody-targeted cell fusionNature Biotechnology, 2004
- Selectively Receptor-Blind Measles Viruses: Identification of Residues Necessary for SLAM- or CD46-Induced Fusion and Their Localization on a New Hemagglutinin Structural ModelJournal of Virology, 2004
- Innate Immune Response Against Nonsegmented Negative Strand RNA VirusesJournal of Interferon & Cytokine Research, 2003
- Measles virus V protein blocks interferon (IFN)‐α/β but not IFN‐γ signaling by inhibiting STAT1 and STAT2 phosphorylationFEBS Letters, 2003
- Measles Virus Infects and Suppresses Proliferation of T Lymphocytes from Transgenic Mice Bearing Human Signaling Lymphocytic Activation MoleculeJournal of Virology, 2003
- A Mouse Model for Glioma: Biology, Pathology, and Therapeutic OpportunitiesToxicologic Pathology, 2000